AT THE FOREFRONT OF THERAPIES FOR RARE DISEASES

43rd Annual J.P. Morgan Healthcare Conference

January 13, 2025



Forward-Looking Statements

This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to the prospects and timing of the potential regulatory and pricing and reimbursement approvals of our products, commercialization plans, manufacturing and supply plans, financing plans, and the projected revenues, profitability and cash position for the Company. The inclusion of forward-looking statements should not be regarded as a representation by us that any of our plans will be achieved. Any or all of the forward-looking statements in this press release may turn out to be wrong and can be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties. For example, statements regarding the goals, progress, timing, and outcomes of discussions with regulatory authorities and pricing and reimbursement authorities, are based on current information. Actual results may differ materially from those set forth in this presentation due to the risks and uncertainties inherent in our business, including, without limitation: the potential that regulatory authorities may not grant or may delay approval for our product candidates; the potential that regulatory inspections may be delayed or not be successful and delay or prevent product approval; the potential that we may not be successful in negotiations with pricing and reimbursement authorities; the potential that we may not be successful in commercializing Galafold and/or Pombiliti and Opfolda in Europe, the U.K., the U.S. and other geographies; the potential that we will not be able to effectively compete in our approved markets: the potential that generic or new competitor products enter the market; the potential that we may not be able to manufacture or supply sufficient clinical or commercial products; and the potential that we will need additional funding to support the manufacturing and commercialization of our products. With respect to statements regarding corporate financial guidance and financial goals and the expected attainment of such goals and projections of the Company's revenue, non-GAAP and GAAP profitability and cash position, actual results may differ based on market factors and the Company's ability to execute its operational and budget plans. In addition, all forward-looking statements are subject to other risks detailed in our Annual Report on Form 10-K for the year ended December 31, 2023, and on Form 10-Q for the quarter ended September 30, 2024. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and we undertake no obligation to revise or update this presentation to reflect events or circumstances after the date hereof.

Non-GAAP Financial Measures

In addition to financial information prepared in accordance with U.S. GAAP, this presentation also contains adjusted financial measures that we believe provide investors and management with supplemental information relating to operating performance and trends that facilitate comparisons between periods and with respect to projected information. These adjusted financial measures are non-GAAP measures and should be considered in addition to, but not as a substitute for, the information prepared in accordance with U.S. GAAP. We typically exclude certain GAAP items that management does not believe affect our basic operations and that do not meet the GAAP definition of unusual or non-recurring items. Other companies may define these measures in different ways. When we provide our expectation for non-GAAP operating expenses on a forward-looking basis, a reconciliation of the differences between the non-GAAP expectation and the corresponding GAAP measure generally is not available without unreasonable effort due to potentially high variability, complexity, and low visibility as to the items that would be excluded from the GAAP measure in the relevant future period, such as unusual gains or losses. The variability of the excluded items may have a significant, and potentially unpredictable, impact on our future GAAP results.



Definition: \ə'mēkəs (noun) *Latin* Friend

Our Passion is for Patients

Our Mission:

We seek to deliver the highest quality therapies for people living with rare diseases

Our Vision:

Be a leader in rare disease drug development and commercialization leveraging our global capabilities in bringing life-changing therapies to patients



A Rare Company

A unique story in biotech with significant revenue growth and profitability

~\$528M 2024 Total Revenue ¹ (+32% Growth) ²	<section-header><section-header><section-header><section-header></section-header></section-header></section-header></section-header>	10-15% FY 2025 Galafold Revenue Growth ²	<section-header><section-header><text></text></section-header></section-header>
65-85% FY 2025 Pombiliti + Opfolda Revenue Growth ²	FY 2024 Non-GAAP Profitability Achieved	Leverageable Global Commercial Organization	\$1B+ Total Revenues Expected in 2028







2024 Key Milestones

Highest Patient Demand for Galafold Since Early Launch

U.S. Galafold IP Settlement with Teva Provides Long Runway of Growth

Galafold: A Fast Growing Treatment in Fabry Disease & SoC in Amenable Population

Non-GAAP Profitability Achieved in 2024

Successful First Year of Launch of Pombiliti + Opfolda

Positive Feedback for Pombiliti + Opfolda Increasing Among Patients and Physicians

Reduced OPEX Guidance and Judiciously Managed Expenses



2025 Strategic Priorities

Deliver total revenue growth of 17-24% at CER¹

2 Double-digit Galafold[®] revenue growth of 10-15% at CER¹

3 Pombiliti[®] + Opfolda[®] revenue growth of 65-85% at CER¹

Advance ongoing studies to broaden labels and strengthen scientific leadership in Fabry and Pompe diseases

Deliver positive GAAP Net Income during H2 2025



4

5

1

Galafold® (migalastat) Continued Growth

Building a leadership position in the treatment of Fabry disease





Fabry Disease Overview

Fabry is a rare inherited genetic disorder caused by mutation in GLA gene and deficiency of α-Gal A enzyme

- >1,000 known mutations
- >18,000 diagnosed WW
- X-linked dominant disease leading to diagnosis of multiple family members

Leading Causes of Death

TRANSIENT ISCHEMIC ATTACK (TIA) & STROKE¹

HEART DISEASE²

- Irregular heartbeat (fast or slow)
- Heart attack or heart failure
- Enlarged heart

KIDNEY DISEASE³

- Protein in the urine
- Decreased kidney function
- Kidney failure

Life-limiting Symptoms

GASTROINTESTINAL³

- Nausea, vomiting, cramping, diarrhea
- Pain/bloating after eating, feeling full
- Constipation
- Difficulty managing weight

PAIN³


FATIGUE³

ANHIDROSIS³



Global Fabry Market

Fabry market expected to grow to ~\$3B by 2029



¹ Global market measured by reported sales of approved therapies for Fabry disease – 2029 sales projected using ~7% CAGR ² LTM ended September 30, 2024

³ Assumes ~40% amenability to Galafold


⁴ Burton 2017 J Pediatr 2017;190:130-5 ; Mechtler *et al.*, The Lancet, 2011 Dec.; Hwu *et al.*, Hum Mutation, 2009 Jun; Spada *et al.*, Am J Human Genet., 2006 Jul

- Significantly underdiagnosed
 - Newborn screening studies suggest Fabry is one of the more prevalent rare genetic diseases (~1:1,500 to ~1:4,000 incidence)⁴
- Continued market growth driven by increased diagnosis
- Anticipate market size for amenable patients to surpass \$1B in 2029
- Galafold continues to be the greatest contributor to market growth



Fabry Market Dynamics

Number of people on a Fabry treatment has more than doubled since 2015



6,000 diagnosed untreated patients remain



2024 Galafold Success (as of December 31, 2024)

Only approved oral treatment in Fabry disease and standard of care for amenable patients




¹ Preliminary and unaudited ² CER: Constant Exchange Rates ³ As of YE 2024

12

Amicus Therapeutics

Galafold Performance

Growing patient demand in 2024 lays foundation for continued strong growth



Global mix of naïve (~60%) and switch (~40%) patients²

Expanding market through uptake in naïve population as well as geographic and label expansion

Maintaining >90% adherence and compliance through HCP and patient education and support

Expect non-linear quarterly growth to continue due to uneven ordering patterns and FX fluctuations


Strong FY 2025 Galafold growth guidance of 10-15% at CER³



3 ¹ Preliminary and unaudited ² Data on file ³ At CER: Constant Exchange Rates

Fabry Market: Significant Remaining Unmet Need

Research suggests there could be >100k people living with Fabry disease who remain undiagnosed



Based on publicly reported sales of Fabry therapies as of September 30, 2024

14

¹Applying incidence of multiple newborn screening studies to population estimates in commercial markets:

Burton 2017 J Pediatr 2017;190:130-5 ; Mechtler et al., The Lancet, 2011 Dec.; Hwu et al., Hum Mutation, 2009 Jun; Spada et al., Am J Human Genet., 2006 Jul



Improving Diagnosis of Fabry Disease

Multiple initiatives leveraging AI and family screening to drive Dx and address health inequities

Collaboration using AI to diagnose Fabry



Renn Medicine



- 580K+ medical records screened
- 100 people with highest risk of Fabry identified
- Outreach ongoing to offer genetic testing

Collaboration for change in health inequity



- Initial findings from Fabry pilot programs in U.K.
 - Minority and low-income groups significantly under-represented
 - >90% of diagnosed Fabry population white
 - ~85% from the least deprived areas
- Initiative already identified low-income families who otherwise wouldn't have been diagnosed

Additional initiatives in several countries ongoing leveraging AI and/or targeted screening



Long-Term Outlook: Clear Path to \$1B+ Galafold Revenue

Many Thousands of Patients and \$1B+ in Peak Sales

Galafold

old (migalastat) cap



Revenue

Global IP protection provides Galafold long runway to becoming a \$1B+ product

The Next 12 Years



Pombiliti[®] (cipaglucosidase alfa-atga) + Opfolda[®] (miglustat)

Potential to establish a new standard of care for people living with late-onset Pompe disease





Pompe Disease Overview

Late-onset Pompe disease is a rare, inherited genetic disorder caused by mutation in GAA gene and deficiency of α-glucosidase enzyme



~5,000-10,000 people diagnosed globally

Respiratory failure is major cause of mortality

Deficiency of GAA leading to lysosomal glycogen accumulation and cellular dysfunction

Symptoms include systemic muscle weakness that worsens over time

Significantly underdiagnosed


~\$1.5B+ global Pompe ERT sales¹



Global Pompe Market

Global Pompe disease market growth continues to be driven by the diagnosis of new patients

Global Pompe Market of ~\$1.5B in 2024 and Tracking toward \$2B+ by 2029¹





An estimated >4,000 Pompe patients globally are being treated by ERT³



¹ Global market measured by reported sales of approved therapies for Pompe disease – 2029 sales projected using ~8% CAGR
² LTM ended September 30, 2024
³ Amicus Data on File from Market Mapping

Pombiliti + Opfolda Profile

The only two-component therapy for the treatment of Pompe disease


- Differentiated mechanism of action combining cipaglucosidase alfa-atga, an ERT, with miglustat, an orally administered enzyme stabilizer
- Only Pompe therapy with Phase 3 study that included ERT-experienced patients
- Phase 3 PROPEL study demonstrated mean improvement in 6MWD and stabilization in FVC in patients switching from SoC





Pombiliti + Opfolda Performance

Successful first full year of launch with revenue of \$70.3M sets foundation for 2025




~50/50 revenue split between U.S. and ex-U.S. exiting 2024



Pombiliti + Opfolda Global Launch Metrics

~220 Individuals Treated or Scheduled Provides Strong Foundation for 2025

Global Launch: Individuals Treated or Scheduled



 ~220 patients have been treated or scheduled to be treated with commercial product

- ~209 treated patients
- ~25 new prescriptions in Q4
- All eligible clinical trial patients from launched markets on commercial therapy by end of 1H24
- New commercial patients time through U.S. insurance process optimized to <30 days
- Patients starting Pombiliti + Opfolda at proportional rate to the respective market share



Geographic Expansion

3 new regulatory approvals and up to 10 new launch countries in 2025

Regulatory

3 additional regulatory approvals anticipated in 2025

Reimbursement

- In 2025, expect to launch in up to 10 new countries, including 4 recent agreements
 - >650 LOPD patients 18+ in those 10 countries
- First commercial patients from those new launch countries anticipated over H1 2025
- Anticipate > 20 individuals switching from clinical trials or early access programs in new countries in 2025

Regulatory approvals anticipated in 2025:



Combined ~150-200 people 18+ living with LOPD and being treated with a Pompe therapy

New reimbursement agreements completed in:



Combined ~200-250 people 18+ living with LOPD and being treated with a Pompe therapy



Ongoing Clinical Studies

Continuing to build the body of evidence to support planned label expansion

Clinical study in children with late-onset Pompe disease (LOPD)



ZP

Clinical study in children with infantile-onset Pompe disease (IOPD)



Amicus registry adding to evidence on differentiated MOA and long-term effect




Pombiliti + Opfolda Real-World Evidence

Ongoing publications demonstrate the impact of Pombiliti + Opfolda's differentiated MOA on long-term outcomes



Pombiliti + Opfolda Growth Drivers

Amicus focused on key drivers of growth in 2025




- Increasing number of net new patients
- Increasing depth and breadth of prescribers
- Expect to launch in up to 10 new countries throughout 2025
- Continuing to drive differentiation through evidence generation and real-world evidence
- Anticipate 90%+ compliance and adherence



Corporate Outlook

Delivering on our mission for patients and shareholders






A Rare Company

A unique story in biotech with significant revenue growth and profitability



Ultimate Measure of Success: Impacting the Lives of People Living with Rare Diseases

29





Thank You





Appendix



Full-Year 2025 Revenue Guidance and Sensitivity

FY 2025 Revenue Guidance ¹	2025
Total Revenue Growth ¹	17% to 24%
Galafold Revenue Growth ¹	10% to 15%
Pombiliti + Opfolda Revenue Growth ¹	65% to 85%

¹ Full-Year 2025 guidance is provided at CER (Constant Exchange Rates) using Full-Year 2024 Average Exchange Rates

FY 2025 Revenue Sensitivity

Given the proportion of Amicus revenue ex-US (~60% in 2024), a change in USD exchange rates of +/- 1% compared to year-end 2024 rates could lead to a ~\$3.6M move in Total Reported Revenues in 2025



Exchange Rates

Q4 2024 Currency Average Rates

FX Rates	Q4 2023	Q4 2024	Variance
USD/EUR	1.076	1.067	(0.8%)
USD/GBP	1.241	1.282	3.3%
USD/JPY	0.007	0.007	(3.0%)

Year-End 2024 vs. Full-Year 2024 Currency Average Rates¹

FX Rates	Year-End 2024	Full-Year 2024	Variance
USD/EUR	1.041	1.082	(3.8%)
USD/GBP	1.255	1.278	(1.8%)
USD/JPY	0.006	0.007	(3.5%)

¹ The variance between **Year-End 2024** and **Full-Year 2024** USD exchange rates of **~4%** would translate into a negative impact of **~\$15M** on Total Revenue in 2025 if rates were to remain at Year-End 2024 level



Distribution of Quarterly Sales

Distribution of Galafold® Revenue by Quarter over Past 5 Years

	Q1	Q2	Q3	Q4
5 Year Avg.	22%	24%	26%	28%



Environmental, Social, & Governance (ESG) Snapshot

Who We Serve

Programs we invest in have 3 key characteristics: Address a rare genetic disease

First-in-class or best-in-class

Impart meaningful benefit for patients

Environmental Management

Committed to producing transformative medicines for people living with rare diseases while practicing environmental responsibility and adhering to sustainability best practices in our operations.

0% Amicus-owned Direct Manufacturing and Related Scope 1 and Scope 2 Emissions

Our mission is to drive sustainability with

our partners by

incorporating

environmental and

sustainability principles

into all our commercial

relationships

(as of December 31, 2023) **Global Employees**

517

3 Female

1 Veteran Status

1 African American

% Female Employees

58%

(as of December 31, 2024) **Board of Directors**

Committed to ongoing Board refreshment and diversity of background, gender, skills, and experience:

Director Diversity

89% Board Independence

Overall Board Diversity

Diversity, Equity, & Inclusion (DEI)

Pledge to support a more inclusive culture to impact our employees, our communities, and society.

> We have embedded DEI into our business units, our Belief Statement, and Mission-**Focused Behaviors**

Employee Recruitment, Engagement, & Retention

Leverage employee capabilities and expertise to provide a culture that drives performance and ultimately attracts, energizes, and retains critical talent.

Amicus is Certified as a Great Place to Work in the U.S., U.K., Italy, Germany, Spain, France, and Japan

Career Development

Employees say Amicus is a great place to work compared to 57% of employees at a typical 90% U.S.-based company



Pledge for a Cure

Designate a portion of product revenue back into R&D for that specific disease until there is a cure.

Pricing PROMISE

Committed to never raising the annual price of our products more than consumer inflation.

Charitable Giving

(as of December 31, 2023) **Contributions allocated:** \$1,980,516 U.S. \$706,417 Intl.

Expanded Access as of Nov. 2024: 40 patients / 16 countries

> Amicus-supported Volunteer hours (U.S.): community programs: 511 37